Exhibit 6

MAIL ROOM DEC 15 1988 PAT. & TRADEMARK OFF.

RECEIVED GROUP 180
DEC 08 1988

6/C White
B. 12/9/88

PATENT

IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE

Application of:	I hereby certify that this paper is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on this date:
FU-KUEN LIN	
Serial No: 113,178	
Filed: October 23, 1987	
For: "PRODUCTION OF ERYTHROPOIETIN"	December 1, 1988 (Date)
Group Art Unit: 183	Jeffrey S. Sharp (31,879) Attorney for Applicant(s)
Examiner: H. E. Schain	

APPLICANT'S AMENDMENT AND REPLY
UNDER 37 C.F.R. §1.111 AND 1.115

and

DECLARATION OF THOMAS W. STRICKLAND
UNDER 37 C.F.R. §1.132

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

This is in response to the Office Action dated June 2, 1988 in the above-identified application wherein claims 1-13, 16, 39-41, 47-49 and 55-57 were variously rejected under 35 U.S.C. §112, 102(b) and 103. Reconsideration and allowance is respectfully requested in view of the following amendments and remarks.

AMENDMENTS

Please amend the above-identified application as follows:

Page 88, line 36, "lablled" should be --labelled--.

Page 91, line 29, please delete "a".

Page 92, line 10, "Table VI" should be --Figure 6--.

Page 95, line 10, "membrances" should be --membranes--.

IN THE CLAIMS

Please cancel claims 1-13, 16, 39-40 and 47-49 without prejudice to Applicant's right to pursue claims of the same or similar scope in a duly filed continuing application.

Please amend claims 41, 55 and 56 as follows:

C1

--41. (Amended) A glycoprotein product having a primary structural conformation and glycosylation sufficiently duplicative of that of a naturally occurring human erythropoietin to allow possession of [one or more of the biological properties thereof] the in vivo biological property of causing bone marrow cells to increase production of reticulocytes and red blood cells and having an average carbohydrate composition which differs from that of naturally occurring human erythropoietin.

C2

55. (Amended) A pharmaceutical composition comprising an effective amount of a [polypeptide] glycoprotein product according to [claims 1, 16, 39, 40 or] claim 41 and a pharmaceutically acceptable diluent, adjuvant or carrier.

tion as reflected by the presently pending claims is clearly warranted.

CONCLUSION

The foregoing amendments and remarks are believed to establish that claims 41, 55-57 and 61-66 are in conformity with all requirements of 35 U.S.C. §112 and are directed to subject matter which is novel and unobvious under 35 U.S.C. §102 and 103. An early notice of allowance thereof is solicited.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BICKNELL

By _____
Jeffrey S. Sharp (Reg. No. 31,879)
Attorneys for Applicants
Two First National Plaza
Chicago, Illinois 60603
(312) 346-5750

Chicago, Illinois
December 1, 1988